UY24958A1 - Antagonistas de gnrh - Google Patents
Antagonistas de gnrhInfo
- Publication number
- UY24958A1 UY24958A1 UY24958A UY24958A UY24958A1 UY 24958 A1 UY24958 A1 UY 24958A1 UY 24958 A UY24958 A UY 24958A UY 24958 A UY24958 A UY 24958A UY 24958 A1 UY24958 A1 UY 24958A1
- Authority
- UY
- Uruguay
- Prior art keywords
- ala
- 4aph
- 4cpa
- xaa10
- 2nal
- Prior art date
Links
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 title 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 2
- HQMLIDZJXVVKCW-UWTATZPHSA-N (2r)-2-aminopropanamide Chemical compound C[C@@H](N)C(N)=O HQMLIDZJXVVKCW-UWTATZPHSA-N 0.000 abstract 1
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 abstract 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 238000011866 long-term treatment Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/11—Gonadotropin; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/837,042 US5925730A (en) | 1997-04-11 | 1997-04-11 | GnRH antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY24958A1 true UY24958A1 (es) | 2001-03-16 |
Family
ID=25273352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY24958A UY24958A1 (es) | 1997-04-11 | 1998-04-13 | Antagonistas de gnrh |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US5925730A (https=) |
| EP (1) | EP1003774B1 (https=) |
| JP (2) | JP4249806B2 (https=) |
| KR (1) | KR100519421B1 (https=) |
| CN (1) | CN1230442C (https=) |
| AR (1) | AR011217A1 (https=) |
| AT (1) | ATE319736T1 (https=) |
| AU (1) | AU728642B2 (https=) |
| BR (1) | BR9808523B1 (https=) |
| CA (1) | CA2286190C (https=) |
| CY (2) | CY1108063T1 (https=) |
| CZ (1) | CZ299097B6 (https=) |
| DE (2) | DE69833751T2 (https=) |
| DK (1) | DK1003774T3 (https=) |
| EE (1) | EE03974B1 (https=) |
| ES (1) | ES2260833T3 (https=) |
| FR (1) | FR09C0028I2 (https=) |
| HR (1) | HRP980197B1 (https=) |
| HU (1) | HU224836B1 (https=) |
| IL (1) | IL132303A0 (https=) |
| LU (1) | LU91585I2 (https=) |
| MY (1) | MY114811A (https=) |
| NL (1) | NL300395I2 (https=) |
| NO (2) | NO324991B1 (https=) |
| NZ (1) | NZ500142A (https=) |
| PL (1) | PL194509B1 (https=) |
| PT (1) | PT1003774E (https=) |
| RU (1) | RU2199549C2 (https=) |
| SI (1) | SI1003774T1 (https=) |
| SK (1) | SK285381B6 (https=) |
| TR (1) | TR199902956T2 (https=) |
| TW (1) | TW505658B (https=) |
| UA (1) | UA58547C2 (https=) |
| UY (1) | UY24958A1 (https=) |
| WO (1) | WO1998046634A1 (https=) |
| ZA (1) | ZA983062B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US5925730A (en) * | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| WO1999026964A1 (en) * | 1997-11-20 | 1999-06-03 | Ortho-Mcneil Pharmaceutical, Inc. | LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES |
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| IL147138A0 (en) * | 2001-12-17 | 2002-08-14 | Yeda Res & Dev | Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation |
| EP2322196A2 (en) | 2003-11-10 | 2011-05-18 | Reprise Biopharmaceutics, LLC | Pharmaceutical compositions including low dosages of desmopressin |
| DE20321887U1 (de) | 2003-11-10 | 2012-01-20 | Allergan, Inc. | Arzneimittel umfassend niedrige Dosierungen von Desmopressin |
| CN101037472B (zh) * | 2006-03-14 | 2013-03-27 | 中国人民解放军军事医学科学院毒物药物研究所 | 具有低组胺释放作用的促黄体生成素释放激素拮抗剂 |
| KR101191322B1 (ko) * | 2006-04-07 | 2012-10-16 | 메리온 리서치 Ⅲ 리미티드 | 증진제를 함유하는 고형 경구용 투여 제형 |
| TWI442932B (zh) * | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| CN107096012A (zh) * | 2008-05-07 | 2017-08-29 | 诺和诺德股份有限公司 | 肽的组合物及其制备方法 |
| US20100215743A1 (en) * | 2009-02-25 | 2010-08-26 | Leonard Thomas W | Composition and drug delivery of bisphosphonates |
| KR101621725B1 (ko) | 2009-04-24 | 2016-05-17 | 폴리펩타이드 라보라토리즈 에이/에스 | 데가렐릭스의 제조 방법 |
| EP2424503B1 (en) * | 2009-05-01 | 2017-07-05 | Ferring BV | Composition for the treatment of prostate cancer |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| WO2011066386A1 (en) | 2009-11-25 | 2011-06-03 | Novetide, Ltd. | Process for production of degarelix |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| WO2011120033A1 (en) * | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| PT2632934T (pt) | 2010-10-27 | 2017-01-06 | Ferring Bv | Processo para o fabrico de degarelix e seus intermediários |
| EP2654772B1 (en) | 2010-12-22 | 2018-09-26 | The Salk Institute for Biological Studies | Cyclic crf antagonist peptides |
| EP2661273A4 (en) | 2011-01-07 | 2014-06-04 | Merrion Res Iii Ltd | IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| WO2013104745A1 (en) | 2012-01-13 | 2013-07-18 | Ferring Bv | Pharmaceutical composition |
| SG11201407679PA (en) | 2012-06-01 | 2014-12-30 | Ferring Bv | Manufacture of degarelix |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| WO2017103275A1 (en) * | 2015-12-17 | 2017-06-22 | Fresenius Kabi Anti-Infectives S.R.L | Process for the manufacture of degarelix and its intermediates |
| CN107778355B (zh) * | 2016-08-25 | 2021-04-20 | 成都圣诺生物制药有限公司 | 一种合成西曲瑞克的方法 |
| WO2019110688A1 (en) | 2017-12-05 | 2019-06-13 | Ferring B.V. | A composition comprising degarelix for use in the treatment of breast cancer |
| EP4004001B1 (en) | 2019-07-29 | 2025-09-03 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrimidinedione compounds and uses thereof |
| US11332495B2 (en) | 2019-09-21 | 2022-05-17 | RK Pharma Solutions LLC | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix |
| CN114456236A (zh) * | 2020-11-09 | 2022-05-10 | 深圳市健翔生物制药有限公司 | 一种地加瑞克乙酰化杂质的制备方法 |
| WO2023072284A1 (zh) | 2021-11-01 | 2023-05-04 | 山东绿叶制药有限公司 | 促性腺素释放激素拮抗剂及其制备方法和应用 |
| WO2026068660A1 (en) | 2024-09-26 | 2026-04-02 | Ferring B.V. | Lipidated gonadotropin releasing hormone analogues |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4547370A (en) * | 1983-11-29 | 1985-10-15 | The Salk Institute For Biological Studies | GnRH Antagonists |
| US4508921A (en) * | 1984-06-28 | 1985-04-02 | Merck & Co., Inc. | Process for preparation of alpha-alkyl amino acids |
| US5073624A (en) * | 1985-04-09 | 1991-12-17 | Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
| US4866160A (en) * | 1985-04-09 | 1989-09-12 | The Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
| US4800191A (en) * | 1987-07-17 | 1989-01-24 | Schally Andrew Victor | LHRH antagonists |
| US4935491A (en) * | 1987-08-24 | 1990-06-19 | Board Of Regents, The University Of Texas System | Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine |
| US5171835A (en) * | 1988-10-21 | 1992-12-15 | The Administrators Of The Tulane Educational Fund | LHRH antagonists |
| US5296468A (en) * | 1989-10-30 | 1994-03-22 | The Salk Institute For Biological Studies | GnRH analogs |
| DE69214818T2 (de) * | 1991-04-25 | 1997-02-27 | Romano S.-Cergue Deghenghi | LHRH-Antagonisten |
| ATE206136T1 (de) * | 1992-12-18 | 2001-10-15 | Abbott Lab | Lhrh antagonisten mit modifizierten aminoacylresten an den positionen 5 und 6 |
| IL108509A0 (en) * | 1993-02-22 | 1994-05-30 | Salk Inst For Biological Studi | GnRH antagonist peptides |
| RU2084458C1 (ru) * | 1993-05-27 | 1997-07-20 | Институт высокомолекулярных соединений РАН | Декапептид, обладающий противоопухолевой активностью |
| US5506207A (en) * | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5843901A (en) * | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| US5925730A (en) * | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
-
1997
- 1997-04-11 US US08/837,042 patent/US5925730A/en not_active Expired - Lifetime
-
1998
- 1998-04-08 AR ARP980101612A patent/AR011217A1/es active IP Right Grant
- 1998-04-09 ZA ZA983062A patent/ZA983062B/xx unknown
- 1998-04-09 MY MYPI98001566A patent/MY114811A/en unknown
- 1998-04-09 HR HR980197A patent/HRP980197B1/xx not_active IP Right Cessation
- 1998-04-13 JP JP54418398A patent/JP4249806B2/ja not_active Expired - Lifetime
- 1998-04-13 DE DE69833751T patent/DE69833751T2/de not_active Expired - Lifetime
- 1998-04-13 WO PCT/US1998/007438 patent/WO1998046634A1/en not_active Ceased
- 1998-04-13 NZ NZ500142A patent/NZ500142A/en not_active IP Right Cessation
- 1998-04-13 BR BRPI9808523-9A patent/BR9808523B1/pt not_active IP Right Cessation
- 1998-04-13 IL IL13230398A patent/IL132303A0/xx active Protection Beyond IP Right Term
- 1998-04-13 PL PL98336213A patent/PL194509B1/pl unknown
- 1998-04-13 EE EEP199900479A patent/EE03974B1/xx active Protection Beyond IP Right Term
- 1998-04-13 PT PT98915539T patent/PT1003774E/pt unknown
- 1998-04-13 TR TR1999/02956T patent/TR199902956T2/xx unknown
- 1998-04-13 AT AT98915539T patent/ATE319736T1/de active
- 1998-04-13 ES ES98915539T patent/ES2260833T3/es not_active Expired - Lifetime
- 1998-04-13 US US09/402,698 patent/US6214798B1/en not_active Expired - Lifetime
- 1998-04-13 HU HU0002704A patent/HU224836B1/hu active Protection Beyond IP Right Term
- 1998-04-13 DK DK98915539T patent/DK1003774T3/da active
- 1998-04-13 UY UY24958A patent/UY24958A1/es not_active Application Discontinuation
- 1998-04-13 EP EP98915539A patent/EP1003774B1/en not_active Expired - Lifetime
- 1998-04-13 CZ CZ0358699A patent/CZ299097B6/cs not_active IP Right Cessation
- 1998-04-13 CN CNB988060337A patent/CN1230442C/zh not_active Expired - Lifetime
- 1998-04-13 CA CA002286190A patent/CA2286190C/en not_active Expired - Lifetime
- 1998-04-13 AU AU69698/98A patent/AU728642B2/en not_active Expired
- 1998-04-13 DE DE200912000033 patent/DE122009000033I2/de active Active
- 1998-04-13 RU RU99123619/04A patent/RU2199549C2/ru not_active IP Right Cessation
- 1998-04-13 UA UA99105726A patent/UA58547C2/uk unknown
- 1998-04-13 SI SI9830832T patent/SI1003774T1/sl unknown
- 1998-04-13 KR KR10-1999-7009315A patent/KR100519421B1/ko not_active Expired - Fee Related
- 1998-04-13 SK SK1396-99A patent/SK285381B6/sk not_active IP Right Cessation
- 1998-05-06 TW TW087106980A patent/TW505658B/zh not_active IP Right Cessation
-
1999
- 1999-10-08 NO NO19994906A patent/NO324991B1/no not_active IP Right Cessation
-
2004
- 2004-11-04 JP JP2004320615A patent/JP3645255B1/ja not_active Expired - Lifetime
-
2006
- 2006-06-07 CY CY20061100747T patent/CY1108063T1/el unknown
-
2009
- 2009-07-03 CY CY2009008C patent/CY2009008I1/el unknown
- 2009-07-15 FR FR09C0028C patent/FR09C0028I2/fr active Active
- 2009-07-17 NL NL300395C patent/NL300395I2/nl unknown
- 2009-07-17 LU LU91585C patent/LU91585I2/fr unknown
- 2009-07-23 NO NO2009016C patent/NO2009016I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY24958A1 (es) | Antagonistas de gnrh | |
| EP1007080B1 (en) | Formulation for the sustained release of peptide agonists and analogues of GnRH | |
| JP3313113B2 (ja) | 雌馬の排卵制御用生体適合性インプラント | |
| Weckermann et al. | Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues | |
| AR023130A1 (es) | Composiciones para promover el crecimiento | |
| NO964434D0 (no) | Bicykliske tiofenderivater og anvendelse som gonadotropinfrigivende hormonantagonister | |
| NI200500087A (es) | Derivados 4-tetrazolyl-4 fenilpiperidina para el tratamiento del dolor | |
| AR098251A2 (es) | Uso de aivlosin o de una sal de adición ácida del mismo farmacológicamente aceptada para la preparación de un medicamento de uso veterinario, un alimento para aves de corral o cerdos, una composición recubierta estable para ser agregada a dicho alimento y un medicamento de uso veterinario | |
| UY27378A1 (es) | Composición farmacéutica | |
| CO5140111A1 (es) | Tratamiento de tumores mediante la administracion de compuestos que induce la liberacion de la hormona de crecimiento y sus antagonistas | |
| ES2163631T3 (es) | Un peptido mejorado, composicion inmunogenica y vacuna o preparacion medica, un procedimiento para inmunizar a los animales contra la hormona lhrh, analogos del peptido lhrh repetidos en tandem y su uso como vacuna. | |
| UA49789C2 (uk) | Застосування димеру лізоциму як лікарського засобу для інгібування біосинтезу фактора некрозу пухлини, спосіб лікування та профілактики захворювань (варіанти), фармацевтична композиція (варіанти), застосування димеру лізоциму як лікарського засобу для профілактики або лікування сніду | |
| ES2078251T3 (es) | Sistema para la distribucion regulada de agentes activos y proceso para su preparacion. | |
| AR008898A1 (es) | Procedimiento convergente para la preparacion de un secretagogo de hormona de crecimiento. | |
| DK1324764T3 (da) | Fremgangsmåde til at opstarte den reproduktive cyklus hos hunlige avlsdyr | |
| Peter et al. | Drug/hormone induced breeding of Chinese teleosts | |
| Mikolajczyk et al. | Modified absorption of sGNRH-a following rectal and oral delivery to common carp, Cyprinus carpio L. | |
| Haider et al. | Induced spawning of maturing Indian catfish, Clarias batrachus (L.), using low doses of steroid hormones and salmon gonadotropin | |
| CR6351A (es) | Composiciones estimulantes del crecimiento mejoradas | |
| HUT62474A (en) | Process for producing veterinary composition with antiparasitic effect | |
| Stacey | Prostaglandins and female sexual behavior in goldfish and other externally fertilizing vertebrates | |
| PT1155014E (pt) | Novos compostos de benzimidazol para serem utilizados como substancias terapeuticas activas processi para a preparacao destes compostos e composicoes farmaceuticas que os contem | |
| Oliveira et al. | Lameness caused by interdigital pouch infection of a Suffolk sheep and its treatment: case report. | |
| Knight | Pheromones in farm animals | |
| KR970032375A (ko) | 황복의 배란을 유도하는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20040310 |